Morphic (MORF)
(Delayed Data from NSDQ)
$55.74 USD
+23.90 (75.06%)
Updated Jul 8, 2024 04:00 PM ET
After-Market: $55.80 +0.06 (0.11%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
MORF 55.74 +23.90(75.06%)
Will MORF be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MORF based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MORF
What Makes Morphic (MORF) a New Buy Stock
Wall Street Analysts See a 56.18% Upside in Morphic Holding, Inc. (MORF): Can the Stock Really Move This High?
MORF: What are Zacks experts saying now?
Zacks Private Portfolio Services
Best Momentum Stocks to Buy for February 14th
New Strong Buy Stocks for February 14th
Wall Street Analysts Think Morphic Holding, Inc. (MORF) Could Surge 57.22%: Read This Before Placing a Bet
Other News for MORF
Morphic Holding, Boeing rise; Paramount, Devon Energy fall, Monday, 7/8/2024
MORF Alert: Monsey Firm of Wohl & Fruchter Investigating Fairness of the Sale of Morphic Holding to Eli Lilly
Lilly to Acquire Morphic to Improve Outcomes for Patients with Inflammatory Bowel Disease
Morphic to Participate in Jefferies Global Healthcare Conference
Viking, CRISPR, Intellia among potential M&A targets: Wells Fargo